Beximco Pharma’s current US portfolio is comprised of six US Food and Drug Administration (FDA) approved productsBeximco Pharmaceuticals Ltd on Tuesday announced the signing of a definitive agreement with Sandoz Inc, a division of Novartis, to acquire a portfolio of eight abbreviated new drug applications (ANDAs) in the US for an undisclosed amount, according to a press release. Beximco Pharma’s current US portfolio is comprised of six US Food and Drug Administration (FDA) approved products. Four of these products are currently being exported to the US and two products are awaiting regulatory approval. Following this transaction, Beximco Pharma’s US portfolio will consist of 14 approved ANDAs. Nazmul Hassan, managing director of Beximco Pharmaceuticals, said: “The acquisition of these ANDAs from Sandoz, a global leader in the generics market, significantly strengthens our position in the US, expanding our portfolio to 14 approved products.

Source: Dhaka Tribune February 19, 2019 19:30 UTC